Kendle Appoints Philip J.W. Davies Vice President, Phase I

May 14, 2008

Company News Release

Position to drive global business strategy required for successful delivery of early stage clinical trials.

Cincinnati, OH-January 14, 2008—Kendle (www.kendle.com), a leading, global full-service clinical research organization (CRO), today announced the appointment of Philip J.W. Davies to the position of vice president, Phase I. Davies will provide global leadership to strengthen and grow the company’s Phase I business which includes a clinical pharmacology unit in The Netherlands and a bioequivalence unit in West Virginia, and will focus on expanding Phase I capabilities globally. Davies will be based in Kendle’s Cincinnati headquarters and will report directly to Candace Kendle, chairman and chief executive officer.

“Phase I is a rapidly growing area of opportunity and is an integral part of Kendle’s business plan, with the market expected to grow between 13.4 and 16 percent annually through 2010,” said Kendle. “I am pleased to welcome Phil to this key leadership role as Kendle focuses on the strategic expansion of our early stage capabilities to meet our customers’ needs.”

Davies brings more than two decades of pharmacology expertise to this position. He joins Kendle from Eli Lilly and Company where he served most recently as director of global exploratory and program phase medical operations. He has been with Eli Lilly since 2001, serving in multiple roles of increasing responsibility, including director, global exploratory medicine operations; director, global clinical pharmacology operations; and director, U.S. clinical pharmacology operations. Prior to Eli Lilly, Davies served as director of Kendle’s clinical pharmacology unit in The Netherlands and previously held clinical pharmacology roles in Germany and the UK.